English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Monitoring of antiplatelet therapy in patients at cardiovascular risk is difficult because existing platelet function tests are too sophisticated for clinical routine. The whole blood TEG ®  Platelet Mapping™ assay measures clot strength as maximal amplitude (MA) and enables for quantification of platelet function, including the contribution of the adenosine diphosphate (ADP) and thromboxane A2 (TxA2) receptors to clot formation.    Methods  In 43 healthy blood donors, the analytical (CV  a  ) and inter-individual variability (CV  g  ) of the TEG ®  Platelet Mapping™ assay were determined together with platelet receptor inhibition in response to arachidonic acid (AA) and ADP.    Results  The CV  a   of the assay for maximal platelet contribution to clot strength (MA  Thrombin  ) was 3.5%, for the fibrin contribution to clot strength (MA  Fibrin  ) 5.2%, for MA  AA   4.5% and for MA  ADP   it was 6.6%. The MA  Thrombin   CV  g   was 2.8%, MA  Fibrin   4.7%, MA  AA   6.6% and for MA  ADP   it was 26.2%. Females had a higher MA  Thrombin   compared to males (62.8 vs. 58.4 mm, p = 0.005). The platelet TxA2 receptor inhibition was 1.2% (range 0–10%) and lower than for the ADP receptor (18.6% (0–58%); p < 0.0001).    Conclusion  The high variability in ADP receptor inhibition may explain both the differences in response to ADP receptor inhibitor therapy and why major bleeding sometimes develops during surgery in patients not treated with ADP receptor inhibitors. An analytical variation of ~5 % for the TEG ®  enables, however, for routine monitoring of the variability in ADP receptor inhibition and of antiplatelet therapy.

Evaluation of the TEG platelet mapping assay in blood donors.